Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ATLCAR.CD30 cells |
Synonyms | |
Therapy Description |
ATLCAR.CD30 cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor that targets CD30, potentially leading to immune response against CD30-positive tumor cells (PMID: 30841880). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ATLCAR.CD30 cells | CAR.CD30-expressing Autologous T Lymphocytes | ATLCAR.CD30 cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor that targets CD30, potentially leading to immune response against CD30-positive tumor cells (PMID: 30841880). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02690545 | Phase Ib/II | ATLCAR.CD30 cells | Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL | Recruiting | USA | 0 |
NCT03049449 | Phase I | ATLCAR.CD30 cells Cyclophosphamide + Fludarabine | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | Completed | USA | 0 |
NCT04083495 | Phase II | ATLCAR.CD30 cells | CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma | Recruiting | USA | 0 |
NCT02663297 | Phase I | ATLCAR.CD30 cells | Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | Active, not recruiting | USA | 0 |